In a report released today, Ami Fadia from Needham reiterated a Buy rating on Immuneering, with a price target of $11.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ami Fadia has given his Buy rating due to a combination of factors that highlight the promising potential of Immuneering’s atebimetinib. The recent case studies from the Phase 2a trials have shown encouraging results, with one patient achieving complete remission and another undergoing a curative-intent procedure due to the deep response to the atebimetinib combination. These outcomes suggest a strong therapeutic potential for the drug, particularly in combination therapies.
Additionally, the management’s focus on advancing the atebimetinib plus mGnP combination in first-line pancreatic ductal adenocarcinoma (PDAC) is noteworthy, with a Phase 3 study expected to commence in the second half of 2026. Furthermore, the initiation of trials combining atebimetinib with Regeneron’s PD-1 inhibitor, Libtayo, in non-small cell lung cancer (NSCLC) further underscores the strategic development of the drug. The clean safety profile and promising early data on circulating tumor DNA (ctDNA) support the potential for atebimetinib to offer a differentiated and durable treatment option in its target indications.
Fadia covers the Healthcare sector, focusing on stocks such as Immuneering, Biogen, and Alkermes. According to TipRanks, Fadia has an average return of 19.4% and a 51.80% success rate on recommended stocks.
In another report released on October 31, Leerink Partners also initiated coverage with a Buy rating on the stock with a $15.00 price target.